555. Targeting kynurenine aminotransferase III: discovery of a selective and brain-penetrant inhibitor for reducing synthesis of immune-induced kynurenic acid
P Fridh, Y Gravenfors, L Schwieler, V Louvrou, M Gómez-Galán, R Caraballo, J Larsson, C Bengtsson, L Dahllund, E Woestenenk, N Nekhotiaeva, H Nordström, A Roos, A Lindqvist, E Johnson, S Erhardt · 2026
Read 555. Targeting kynurenine aminotransferase III: discovery of a selective and brain-penetrant inhibitor for reducing synthesis of immune-induced kynurenic acid by P Fridh, Y Gravenfors, L Schwieler, V Louvrou, M Gómez-Galán, R Caraballo, J Larsson, C Bengtsson, L Dahllund, E Woestenenk, N Nekhotiaeva, H Nordström, A Roos, A Lindqvist, E Johnson, S Erhardt (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13556811.txt.
Description
P Fridh and a large team report the discovery of a new enzyme blocker in 2026. The target enzyme helps make kynurenic acid in the brain during immune activity. Raised levels of that acid are linked to psychosis and poor thinking.
Under normal conditions, a sister enzyme does most of this work. During infection or immune stress, the target enzyme takes a larger role. The new blocker was designed to be selective and to reach the brain. Early tests check whether it cuts acid making as intended. Readers learn how drug design can aim at one phase of a pathway, not the whole path.
Catalog record
| CREATOR | P Fridh, Y Gravenfors, L Schwieler, V Louvrou, M Gómez-Galán, R Caraballo, J Larsson, C Bengtsson, L Dahllund, E Woestenenk, N Nekhotiaeva, H Nordström, A Roos, A Lindqvist, E Johnson, S Erhardt |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 3 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |